Connect Biopharma Holdings Limited
CNTB
$2.05
-$0.10-4.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -91.85% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -91.85% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -91.85% | -- | -- | -- | -- |
| SG&A Expenses | 30.35% | 31.67% | 25.78% | 5.80% | -12.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 87.87% | 275.73% | -- | 277.05% | 161.41% |
| Total Operating Expenses | -3.76% | -21.81% | -24.68% | -31.27% | -36.96% |
| Operating Income | -60.08% | 61.86% | 62.38% | 62.78% | 63.45% |
| Income Before Tax | -82.07% | 66.71% | 72.74% | 72.22% | 72.13% |
| Income Tax Expenses | 134.48% | 109.32% | 85.83% | -9.65% | -54.83% |
| Earnings from Continuing Operations | -82.31% | 66.34% | 72.43% | 72.06% | 72.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.31% | 66.34% | 72.43% | 72.06% | 72.09% |
| EBIT | -60.08% | 61.86% | 62.38% | 62.78% | 63.45% |
| EBITDA | -61.37% | 62.46% | 62.92% | 63.26% | 63.89% |
| EPS Basic | -81.21% | 66.53% | 72.53% | 72.10% | 72.08% |
| Normalized Basic EPS | -95.08% | 67.87% | 73.70% | 72.66% | 72.19% |
| EPS Diluted | -80.33% | 66.42% | 72.41% | 71.92% | 71.87% |
| Normalized Diluted EPS | -93.87% | 67.60% | 73.46% | 72.45% | 72.01% |
| Average Basic Shares Outstanding | 0.44% | 0.36% | 0.27% | 0.20% | 0.14% |
| Average Diluted Shares Outstanding | 0.20% | 0.59% | 0.50% | 0.44% | 0.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |